Fractionation of guinea pig leukocyte by flow cytometry using a novel MIL4/SSC parameter
スポンサーリンク
概要
- 論文の詳細を見る
- 2003-06-20
著者
-
Yamamoto N
Aids Research Center National Institute Of Infectious Diseases
-
HONDA Mitsuo
AIDS Research Center, National Institute of Infectious Diseases
-
Yamamoto Naoki
Department Of Microbiology School Of Medicine Tokyo Medical And Dental University
-
Honda Mitsuo
Aids Research Center
-
Honda M
Aids Research Center National Institute Of Infectious Diseases
-
CHIBA Jo
Faculty of Industrial Science and Technology, Tokyo University of Science
-
HAGA Shinji
Department of Bacteriology, National Institute of Infectious Diseases
-
TAKIZAWA Mari
国立感染症研究所 エイズ研究センター
-
CHIBA Jo
国立感染症研究所 エイズ研究センター
-
HAGA Shinji
国立感染症研究所 エイズ研究センター
-
ASANO Toshihiko
国立感染症研究所 エイズ研究センター
-
YAMAMOTO Naoki
国立感染症研究所 エイズ研究センター
-
HONDA Mitsuo
国立感染症研究所 エイズ研究センター
-
Chiba Jo
Faculty Of Industrial Science And Technology Tokyo University Of Science
-
Haga Shinji
Department Of Bacteriology National Institute Of Infectious Diseases
-
Takizawa M
Department Of Life Sciences The University Of Tokyo
-
Takizawa M
Aids Research Center National Institute Of Infectious Diseases
関連論文
- Trichothecene Mycotoxins Inducd Apoptosis In Vitro and In Vivo
- "A-14 T-2 Toxin induced Apoptosis in Human Peripheral Blood Lymphocytes in vitro and Mouse Thymus in vivo.
- An elevation of intracellular calcium and an induction of apoptosis by T-2 toxin in HL-60 cells.
- Synthesis of a CC Chemokine, vMIP-II, Encoded by Kaposi's Sarcoma-Associated Herpesvirus and Its Biological Activity
- Development of the Chemokine Receptor CXCR4 Antagonists as Multi-Pharmaceutical Agents Involving a New Class of Low Molecular Weight Antagonists
- Synthesis and Biological Evaluation of Peptidomimetic Analogs of the CXCR4 Antagonist FC131
- The Chemokine Receptor CXCR4 as a Therapeutic Target for Several Diseases Including AIDS, Cancer and Rheumatoid Arthritis
- New Leads of Low Molecular Weight CXCR4 Antagonists Based on Enhancement of the T140-based Pharmacophores
- CXCR4 Antagonists Identified as Anti-Cancer-Metastatic Agents
- HIV-cell Fusion Inhibitors Targeted to the HIV Second Receptor : T22 and Its Downsized Analogs with High Activity